BACKGROUND: Treatment of complicated skin and skin structure infection (cSSSI) places a tremendous burden on the health care system. Understanding relative resource utilization associated with different antimicrobials is important for decision making by @entity1 , health care providers, and payers. METHODS: The authors conducted an open-label, pragmatic, randomized (1:1) clinical study (N   =   250) to compare the effectiveness of @entity13757 with that of @entity2176 for treatment of @entity1 hospitalized with cSSSI caused by suspected or documented @entity3256 -resistant @entity794 infection. The primary study end point was infection-related length of stay (IRLOS). Secondary end points included health care resource utilization, cost, clinical response, and @entity1 -reported outcomes. @entity1 assessments were performed daily until the end of antibiotic therapy or until hospital discharge, and at 14  days and 30  days after discharge. RESULTS: No difference was found for IRLOS, total LOS, and total inpatient cost between cohorts. Hospital LOS contributed 85.9  % to the total hospitalization cost, compared with 6.4  % for drug costs. @entity13757 showed a nonsignificant trend toward a higher clinical success rate, compared with @entity2176 , at treatment days 2 and 3. In the multivariate analyses, @entity2176 was associated with a lower likelihood of day 2 clinical success (odds ratio [OR]   =   0.498, 95  % confidence interval [CI], 0.249-0.997; P   <   0.05). CONCLUSION: This study did not provide conclusive evidence of the superiority of one treatment over the other in terms of clinical, economic, or @entity1 outcomes. The data suggest that physician and @entity1 preference, rather than drug acquisition cost, should be the primary driver of initial antibiotic selection for hospitalized @entity1 with cSSSI. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01419184 (Date: August 16, 2011).

An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of @entity13757 versus XXXX for the treatment of complicated skin and skin structure infection.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient'] @entity3256 :: ('MESH:D008712', 'Chemical') :: ['methicillin'] @entity2176 :: ('MESH:D014640', 'Chemical') :: ['vancomycin'] @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus'] @entity13757 :: ('MESH:D017576', 'Chemical') :: ['Daptomycin', 'daptomycin']
@entity2176 :: (MESH:D014640,Chemical) :: ['vancomycin']
